Almost the entire biotech industry has been this way for decades once the small molecule patent cliff hit pharma and the R&D costs for therapies skyrocketed. If you look at biotech IPOs, the majority of the startups IPO pre-revenue, long before they’re even legally allowed to sell anything.
Which is totally fine: anyone who is a biotech investor knows this and everyone makes tons of money in this arrangement. Investors (both public and private) take on the science risk and some of the regulatory risk, and the pharmaceutical companies provide a guaranteed (big $$$) exit and take over scaling manufacturing to bring a drug to market. Most people with retirement accounts and pensions and index funds rarely touch this stuff except as a diversification strategy that pools the risky stuff to get the upside on the whole industry.
It's the same in medical devices. Most startups take it from idea through R&D then go public or are acquired right as they go through FDA approval or submit for it.
Which is totally fine: anyone who is a biotech investor knows this and everyone makes tons of money in this arrangement. Investors (both public and private) take on the science risk and some of the regulatory risk, and the pharmaceutical companies provide a guaranteed (big $$$) exit and take over scaling manufacturing to bring a drug to market. Most people with retirement accounts and pensions and index funds rarely touch this stuff except as a diversification strategy that pools the risky stuff to get the upside on the whole industry.